Normal view MARC view ISBD view

Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.

Smith, Michael A

Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases. [electronic resource] - The Annals of pharmacotherapy Dec 2014 - 1629-35 p. digital

Publication Type: Journal Article; Review

ISSN: 1542-6270

Standard No.: 10.1177/1060028014549799 doi

Subjects--Topical Terms:
Animals
Antibodies, Monoclonal, Humanized--adverse effects
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Colitis, Ulcerative--drug therapy
Crohn Disease--drug therapy
Humans
Inflammatory Bowel Diseases--drug therapy
Integrins--antagonists & inhibitors
Male

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)